We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Objectives
- Definition of neoplasia
- Terminology difference
- What is a neoplasm composed of?
- Types of neoplasm?
- Benign vs. malignant neoplasms
- Differences between sarcomas and carcinomas
- Tumor immunology
- Immunosurveillance
- Tumor specific antigens
- Tumor-associated antigens
- Oncogenic viral antigens
- Differentiation antigens
- Antibodies
- Cytotoxic T Lymphocytes (CTL)
- Natural killer cells
- Macrophages
- Tumor evasion mechanisms: strategies
- Tumor evasion mechanisms (1)
- Tumor evasion mechanisms (2)
- Tumor immunotherapy
- Immune checkpoint therapy
- Chimeric Antigen Receptors (CARs)
- Adoptive cellular immunotherapy
- Antibody therapies
- Antibody therapies: immunoconjugates
- Purging bone marrow of tumor cells
- Tumor vaccines
- Summary
- Thank you
- Financial disclosures
Topics Covered
- Neoplasia
- Cancer terminology
- Tumor antigen types
- Anti-tumor immunity
- Tumor evasion mechanisms
- Tumor immunotherapy and checkpoint therapies
- Antibody therapies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Fang, Y. (2026, March 31). Immune response to neoplasia [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2026, from https://doi.org/10.69645/OKAN9817.Export Citation (RIS)
Publication History
- Published on March 31, 2026
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Series: Introduction to Clinical Pathology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, everybody. I'm
excited to discuss with you
about cancer immunology today.
This is Dr. Fang from
Des Moines University.
I'm from the Department
of Microbiology,
Immunology, and Pathology.
I also hold an adjunct position
in the Department of Surgery
at the University of Missouri.
This topic is about immune
response to neoplasia.
0:30
First, as usual, I
would like to give you
the clear objectives to
prepare your learning aims.
So that's the objectives.
We would like to say you need to
describe tumor
antigen types and the
feasibility of using
these antigens as targets
for your future
cancer immunotherapy.
After this lecture, you
should explain well about
cell types and also humoral
factors in anti-tumor immunity.
Also, I would like
you to understand
the ways tumor cells evade
detection and eradication
by the host immune system.
Also, I want you to
list approaches using
antibodies as a way
against cancer.
I would like you to explain
further about the approaches
to eliminate tumor cells by
adoptive cellular immunity.
The last part I would
like you to know is how
cytokine therapy may be
used to treat tumors.
These are the major objectives.